Evidence map›Paper›PMID 34819038›Full record

ArticleBMC cancer2021

Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer.

Xiaotao Li, Shi Fu, Yinglong Huang, Ting Luan, Haifeng Wang, Jiansong Wang

Abstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaotao LiDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 347, Dianmian street, Wuhua District, Kunming, 650101, Yunnan, People's Republic of China.
Shi FuDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 347, Dianmian street, Wuhua District, Kunming, 650101, Yunnan, People's Republic of China.
Yinglong HuangDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 347, Dianmian street, Wuhua District, Kunming, 650101, Yunnan, People's Republic of China.
Ting LuanDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 347, Dianmian street, Wuhua District, Kunming, 650101, Yunnan, People's Republic of China.
Haifeng WangDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 347, Dianmian street, Wuhua District, Kunming, 650101, Yunnan, People's Republic of China. highphone@126.com.
Jiansong WangDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 347, Dianmian street, Wuhua District, Kunming, 650101, Yunnan, People's Republic of China. jiansongwangkm@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBladder cancer (BC) is one of the most common malignancies and has a relatively poor outcome worldwide. In this study, we attempted to construct a novel metabolism-related gene (MRG) signature for predicting the survival probability of BC patients.

methodsFirst, differentially expressed MRGs between BC and normal samples were identified and used to construct a protein-protein interaction (PPI) network and perform mutation analysis. Next, univariate Cox regression analysis was utilized to select prognostic genes, and multivariate Cox regression analysis was applied to establish an MRG signature for predicting the survival probability of BC patients. Moreover, Kaplan-Meier (KM) survival analysis and receiver operating characteristic (ROC) analysis were performed to evaluate the predictive capability of the MRG signature. Finally, a nomogram based on the MRG signature was established to better predict the survival of BC.

resultsIn the present study, 27 differentially expressed MRGs were identified, most of which presented mutations in BC patients, and LRP1 showed the highest mutation rate. Next, an MRG signature, including MAOB, FASN and LRP1, was established by using univariate and multivariate Cox regression analysis. Furthermore, survival analysis indicated that BC patients in the high-risk group had a dramatically lower survival probability than those in the low-risk group. Finally, Cox regression analysis showed that the risk score was an independent prognostic factor, and a nomogram integrating age, pathological tumor stage and risk score was established and presented good predictive ability.

conclusionWe successfully constructed a novel MRG signature to predict the prognosis of BC patients, which might contribute to the clinical treatment of BC.

Indexed as

Gene Expression ProfilingMutationTranscriptomeAge FactorsDatabases, GeneticFatty Acid Synthase, Type IFemaleGene OntologyHumansKaplan-Meier EstimateLow Density Lipoprotein Receptor-Related Protein-1MaleMiddle AgedMonoamine OxidaseNomogramsProportional Hazards ModelsFASN protein, humanFatty Acid Synthase, Type ILow Density Lipoprotein Receptor-Related Protein-1LRP1 protein, humanMonoamine OxidaseBladder cancerGEOMetabolism-related genePrognosisTCGA

Identifiers

PMID34819038
PMCPMC8611960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.